TILS.L Share News (TILS)
TILS Share
TILS Share
TILS Share
TILS Share
TILS
TILS Share
TILS Broker
TILS Directors
TILS Financial
TILS
TILS Short
TILSTue, 18th May 2021 21:38
Tiziana Life Sciences PLC - London-based therapeutics for oncology, inflammation and infectious diseases - Pretax loss in 2020 widens to GBP22.1 million from GBP7.8 million. Widened loss partly down to company paying GBP10.3 million in realisation bonus, compared to no such costs in 2019.
Current stock price: 71.99 pence, down 5.2% on Tuesday
Year-to-date change: down 21%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Tiziana Life Sciences has been granted an exclusive license to develop and commercialise Novimmune SA's CD3 receptor monoclonal antibody foralumab. Foralumab can be utilised for a range of autoimmune and inflammatory diseases, such multiple sclerosis, type-1 diabetes, inflammatory bowel disease, pso
Read more